Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex992.htm |
EX-99.1 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex991.htm |
EX-5.1 - OPINION ON LEGALITY - Sanara MedTech Inc. | smti_ex51.htm |
EX-1.1 - UNDERWRITING AGREEMENT - Sanara MedTech Inc. | smti_ex11.htm |
8-K - CURRENT REPORT - Sanara MedTech Inc. | smti_8k.htm |
Exhibit 99.3
Sanara MedTech Inc. Announces Closing of $31.6 Million Public
Offering and Full Exercise of the Underwriters’ Option to
Purchase Additional Shares
FORT WORTH, TX / ACCESSWIRE / February 17, 2021 / Sanara
MedTech Inc.
Based in Fort Worth, Texas, Sanara MedTech Inc.
(“Sanara,” the “Company,” “we,”
“our” or “us”) (NASDAQ: SMTI), a provider
of wound and skin care products dedicated to improving patient
outcomes, today announced the closing of its underwritten public
offering of 1,265,000 shares of common stock at a public offering
price of $25.00 per share, including 165,000 shares of common stock
issued pursuant to the full exercise by the underwriters of their
option to purchase additional shares of common stock, resulting in
gross proceeds of $31.6 million, before deducting underwriting
discounts and commissions and estimated offering
expenses.
Cantor Fitzgerald & Co. acted as the sole book-running manager
for the offering.
Sanara expects to use the net proceeds from the offering to expand
its salesforce and for further development of its products,
services and technologies pipeline, clinical studies and general
corporate purposes, including working capital.
A shelf registration statement relating to the shares of common
stock offered in the offering was previously filed with the
Securities and Exchange Commission (“SEC”) and declared
effective by the SEC on January 4, 2021. A final prospectus
supplement and accompanying base prospectus related to the offering
have been filed with the SEC and are available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and the accompanying base prospectus may also be obtained from
Cantor Fitzgerald & Co., 499 Park Avenue, 6th Floor, New York,
NY 10022, Attn: Capital Markets Department, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based
healing solutions and services, Sanara MedTech Inc. markets and
distributes wound and skin care products and is seeking to offer
wound care and dermatology virtual consultation services via
telemedicine to physicians, hospitals, clinics, and all post-acute
care settings. Sanara’s products are primarily sold in the
North American advanced wound care and surgical tissue repair
markets. Sanara MedTech markets and distributes CellerateRX®
Surgical Activated Collagen® to the surgical markets as well
as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser,
BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™
Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™
Hydrolyzed Collagen Powder and Gel. We are constantly seeking
long-term strategic partnerships with a focus on products and
technologies that improve outcomes at a lower overall cost. In
addition, Sanara is actively seeking to expand within its six focus
areas of wound and skin care for the acute, post-acute, and
surgical markets. The focus areas are debridement, biofilm removal,
hydrolyzed collagen, advanced biologics, negative pressure wound
therapy adjunct products, and the oxygen delivery system segment of
the healthcare industry.
Forward-Looking Statements
The statements in this press release that do not constitute
historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “may,”
“will,” “would,” “should,”
“expect,” “plan,” “anticipate,”
“could,” “intend,” “target,”
“project,” “contemplates,”
“believes,” “estimates,”
“predicts,” “preliminary,”
“potential” or “continue” or the negatives
of these terms, variations of these terms or other similar
expressions. These forward-looking statements include statements
regarding the expected use of proceeds from the offering, the
development of new products and expansion of the Company’s
business in telehealth and wound care. These items involve risks,
contingencies and uncertainties such as the extent of product
demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and
integrate acquisitions, and other risks, contingencies and
uncertainties detailed in the Company’s SEC filings, which
could cause the Company’s actual operating results,
performance or business plans or prospects to differ materially
from those expressed in, or implied by these
statements.
All forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to revise
any of these statements to reflect the future circumstances or the
occurrence of unanticipated events, except as required by
applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.